Skip to main content
SpringerLink
Log in

Optimal follow-up of endometrial cancer patients

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Gynecological malignancies account round 10 % of all female cancers, with the uterine cancer being the most predominant one. Surveillance programs of all gynecologic cancers are primarily based on recurrence rates, timing of recurrence, salvage options and chances for cure of patient with recurrence. Since there is no prospective, high evidence data about optimal surveillance program after primary treatment of patients with endometrial cancer recommendations are based on review of retrospective data sets. From all the diagnostic tools available, history taking and clinical examination, including comprehensive gynecological examination, still contribute to the greatest number of recurrence detection. Radiologic tests are usually employed when a suspicion of recurrence is raised. Follow-up plan should be tailored according to the estimated risk of relapse for individual patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Creutzberg CL, van Putten WLJ, Koper PCM, et al. for the PORTEC Study Group. Surgery and radiotherapy versus surgery alone for patients with stage –1 endometrial carcinoma: multicentre randomised trial. Lancet. 2000;355:1404–11.

    Article  CAS  PubMed  Google Scholar 

  2. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.

    Article  PubMed  Google Scholar 

  3. Nout RA, Smit VTHBM, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.

    Article  CAS  PubMed  Google Scholar 

  4. Ben Arie A, Lavie O, Gdalevich M, et al. Temporal pattern of recurrence of stage I endometrial cancer in relation to histological risk factors. Eur J Surg Oncol. 2012;38(2):166–9.

    Article  CAS  PubMed  Google Scholar 

  5. Simpkins F, Papadia A, Kunos C, et al. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular invasion. Int J Gynecol Cancer. 2013;23(1):98–104.

    Article  PubMed  Google Scholar 

  6. Fung-Kee-Fung M, Dodge J, Elit L, et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol. 2006;101:520–9.

    Article  PubMed  Google Scholar 

  7. Milgrom SA, Kollmeier MA, Abu-Rustum NR, O’Cearbhaill RE, Barakat RR, Alektiar KM. Quantifying the risk of recurrence and death in stage III (FIGO 2009) endometrial cancer. Gynecol Oncol 2014;134:297–301. http://dx.doi.org/10.1016/j.ygyno. Accesssed: 13 May 2014.

    Article  PubMed  Google Scholar 

  8. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–7.

    Article  CAS  PubMed  Google Scholar 

  9. Ayeni TA, Bakkum-Gamez JN, Mariani A, et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol. 2013;129:478–85.

    Article  PubMed  Google Scholar 

  10. Sartori E, Pasinetti B, Chiudinelli F, et al. Surveillance procedures for patients treated for endometrial cancer: a review of the literature. In J Gynecol Cancer. 2010;20(6):985–92.

    Article  Google Scholar 

  11. Sartori E, Lafare B, Gadducci a, et al. Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study. Int J Gynecol Cancer. 2003;13:458–65.

    Article  CAS  PubMed  Google Scholar 

  12. Moschiano EJ, Barbuto DA, Walsh C, et al. Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; vaginal versus other sites. Int J Gynecol Pathol. 2014;33:268–73.

    Article  CAS  PubMed  Google Scholar 

  13. Gaducci A, Cosio S, Fanucci A, Cristofani R, Genazzani AR. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. Anticancer Res. 2000;20:1977–84.

    Google Scholar 

  14. Salani R, Backes FJ, Fung Kee Fung M Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011;204:466–78.

    Article  PubMed  Google Scholar 

  15. Smith CJ, Heeren M, Nicklin JL, et al. Efficacy of routine follow-up in patients with recurrent uterine cancer. Gynecol Oncol. 2007;107:124–9.

    Article  PubMed  Google Scholar 

  16. Tjalma WAA, Van Dam PA, Makar AP, Cruickshank DJ. The clinical value and the coseffectiveness of follow-up in endometrial cancer patients. Int J Gynecol Cancer. 2004;14:931–7.

    Article  CAS  PubMed  Google Scholar 

  17. Aung L, Howells RE, Lim KC, Hudson E, Jones PW. Why routine clinical follow-up for patients with early stage endometrial cancer is not always necessary: a study on women in South Wales. Int J Gynecol Cancer. 2014;24:556–63.

    Article  PubMed  Google Scholar 

  18. Zakhour M, Li AJ, Walsh CS, Cass I, Karlan BY, Rimel BJ. Post treatment surveillance of type II endometrial cancer patients. Gynecol Oncol. 2013;131(3):609–12.

    Article  PubMed  Google Scholar 

  19. Carrara L, Gadducci A, Landoni F, et al. Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis. Int J Gynecol Cancer. 2012;22(6):1013–9.

    Article  PubMed  Google Scholar 

  20. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):33–8.

    Google Scholar 

  21. Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. Can Med Assoc. 1997;157:879–86.

    CAS  Google Scholar 

  22. Bristow RE, Purinton SC, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL 2nd. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol. 2006;103:709–13.

    Article  PubMed  Google Scholar 

  23. Kew FM, Roberts AP, Cruickshank DJ. The role of routine follow-up after gynecological malignancy. Int J Gynecol Cancer. 2005;15:413–9.

    Article  CAS  PubMed  Google Scholar 

  24. Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol. 2000;95:692–6.

    Article  CAS  PubMed  Google Scholar 

  25. Kadkhodayan S, Shahriari S, Treglia G, Yousefi Z, Sadeghi R. Accuracy of 18-F-FDG PET imaging in the follow-up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol Oncol. 2013;128(2):397–404.

    Article  PubMed  Google Scholar 

  26. Ozcan Kara P, Kara T, Kaya Bm Kara Gedik G, Sari O. The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: a comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker. Rev Esp Med Nucl Imagen Mol. 2012;31(5):257–60.

    CAS  PubMed  Google Scholar 

  27. Kitajima K, Suzuki K, Nakamoto Y, et al. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence. Eur J Radiol. 2012;81:3557–62.

    Article  PubMed  Google Scholar 

  28. Testa AC, Legge A D, Virgilio B, et al. Which imaging technique should we use in the follow-up of gynaecological cancer? Best Pract Res Clin Obstet Gynaecol 2014;28:769–91

    Article  PubMed  Google Scholar 

  29. Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE. Serial serum Ca 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol. 1994;84:12–6.

    CAS  PubMed  Google Scholar 

  30. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother. 2004;58(1):24–38.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic for Oncology and Radiotherapy, Clinical Hospital Centre Split, Spinčićeva 1, 21 000, Split, Croatia

    Eduard Vrdoljak MD, PhD, Tihana Boraska Jelavić MD, PhD & Branka Petrić Miše MD, PhD

Authors
  1. Eduard Vrdoljak MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tihana Boraska Jelavić MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Branka Petrić Miše MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduard Vrdoljak MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vrdoljak, E., Boraska Jelavić, T. & Petrić Miše, B. Optimal follow-up of endometrial cancer patients. memo 8, 62–65 (2015). https://doi.org/10.1007/s12254-015-0202-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-015-0202-z

Keywords

Search

Navigation